Recombinant CTLA-4 (Ipilimumab Biosimilar) 抗体
This Humanized 单克隆 antibody specifically detects CTLA-4 (Ipilimumab Biosimilar) in FACS 和 in vivo. It exhibits reactivity toward 人.
产品编号 ABIN7200671
发货至:
中国
Contact our Customer Service for availability and price in your country.
Contact Info
Our Local Distributor
中国
北京 101111
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
Quick Overview for Recombinant CTLA-4 (Ipilimumab Biosimilar) 抗体 (ABIN7200671)
抗原
CTLA-4 (Ipilimumab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
Humanized
克隆类型
单克隆
标记
This CTLA-4 (Ipilimumab Biosimilar) antibody is un-conjugated
应用范围
Flow Cytometry (FACS), In vivo Studies (in vivo)
质量等级
Research Grade
-
-
原理
- Ipilimumab Biosimilar, Human CTLA-4 Monoclonal Antibody
-
特异性
- The in vivo grade ipilimumab biosimilar specifically binds to the human CTLA4.
-
产品特性
- What is Ipilimumab biosimilar research grade? Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.
-
纯化方法
- Protein A or G affinity column
-
纯度
- >95 % by reducing SDS-PAGE
-
过滤
- 0.2 μm filtered
-
内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method
-
免疫原
- The anti-human CTLA-4 monoclonal antibody ipilimumab biosimilar was produced in the ipilimumab biosimilar CHO stable cell line.
-
亚型
- IgG4
-
-
anti-CTLA-4 (Ipilimumab Biosimilar) antibody
Research Grade 适用: 人 FACS, ELISA 宿主: Human Monoclonal unconjugated Recombinant Antibody
-
-
应用备注
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ipilimumab.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- > 3 mg/mL
-
缓冲液
- PBS, pH 7.4, no stabilizers or preservatives.
-
储存液
- Without preservative
-
储存条件
- 4°C,-20 °C
-
储存方法
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
-
有效期
- 12 months
-
-
- CTLA-4 (Ipilimumab Biosimilar)
-
别名
- Ipilimumab Biosimilar
-
物质类
- Biosimilar
抗原
-
You are here:
